Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.
The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.
van Oeveren
Arjan
A
Discovery Research, Ligand Pharmaceuticals Inc., 10275 Science Center Drive, San Diego, California 92121, USA. avanoeveren@ligand.com
Motamedi
Mehrnouch
M
Mani
Neelakandha S
NS
Marschke
Keith B
KB
López
Francisco J
FJ
Schrader
William T
WT
Negro-Vilar
Andrés
A
Zhi
Lin
L
D000284:Administration, Oral; D000634:Aminoquinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000728:Androgens / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008958:Models, Molecular; D009919:Orchiectomy; D009929:Organ Size; D017773:Pelvic Floor / Q000033:anatomy & histology; D011467:Prostate / Q000033:anatomy & histology / Q000187:drug effects; D011804:Quinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D015363:Quinolones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D011944:Receptors, Androgen / Q000187:drug effects* / Q000378:metabolism; D013329:Structure-Activity Relationship; D014162:Transfection
C515129:6-N,N-bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one; D000634:Aminoquinolines; D000728:Androgens; D011804:Quinolines; D015363:Quinolones; D011944:Receptors, Androgen